MDL 3176 consolidates claims from GLP-1 users who developed NAION — non-arteritic anterior ischemic optic neuropathy — a condition where blood supply to the optic nerve is suddenly blocked, causing irreversible vision loss or blindness. This is a separate MDL from the GI injury track (MDL 3094, gastroparesis). The science is anchored by a July 2024 JAMA Ophthalmology study finding a 4.28x increased NAION risk in diabetic semaglutide users and a 7.64x risk in obese semaglutide users. With 50+ million GLP-1 prescriptions written in the U.S., the qualifying plaintiff population is enormous.
GLP-1 receptors are expressed in retinal ganglion cells and optic nerve tissue. Proposed mechanism: semaglutide alters blood viscosity and microvascular autoregulation, reducing optic nerve perfusion. The JAMA Ophthalmology study (Mass Eye and Ear / Harvard, 2024) found statistically significant increased NAION risk in two independent patient cohorts. Failure-to-warn is the primary theory — Novo Nordisk and Eli Lilly are alleged to have known of ophthalmological risk signals and failed to update labeling.
MDL 3176 was formed in late 2025 specifically for GLP-1 vision loss claims — NAION (non-arteritic anterior ischemic optic neuropathy), sometimes called an "optic nerve stroke." This is a completely separate MDL from the gastroparesis/GI track (MDL 3094). A landmark JAMA Ophthalmology study (July 2024) found semaglutide users had 4x the risk of NAION compared to non-users. With tens of millions of GLP-1 prescriptions written, the qualifying plaintiff population is massive. Heavy plaintiff attorney advertising expected throughout 2026.